Cyclosporine A for Refractory Interstitial Cystitis/Bladder Pain Syndrome: Experience of 3 Tertiary Centers

Urologic Specialists of Oklahoma, Inc., Tulsa, Oklahoma.
The Journal of urology (Impact Factor: 4.47). 08/2012; 188(4):1186-91. DOI: 10.1016/j.juro.2012.06.023
Source: PubMed


Cyclosporine A is a fifth-tier treatment option in the American Urological Association guidelines for interstitial cystitis/bladder pain syndrome. It was more effective than pentosanpolysulfate in a Finnish trial, but experience elsewhere is limited. Some centers use cyclosporine A off label for carefully selected patients but the number of patients in each center is small. We performed a retrospective review combining data from 3 tertiary centers that focus on interstitial cystitis/bladder pain syndrome.
Charts were reviewed for patients with interstitial cystitis/bladder pain syndrome who received cyclosporine A. Response was defined as markedly improved on the 7-point global response assessment (2 centers) or as at least a 50% decrease in Interstitial Cystitis Symptom Index score (1 center).
The study included 14 men and 30 women. Mean patient age was 55.5 years (range 27 to 75) and mean followup was 20.8 months (range 3 to 81). A total of 34 patients had Hunner lesions. Of these patients 29 (85%) responded but 6 eventually stopped cyclosporine A for adverse events, resulting in a success rate of 68% (23 of 34) for patients with Hunner lesions. In contrast, only 3 of 10 patients without Hunner lesions responded (30%). For all responders, the response occurred within 4 months.
Cyclosporine A had a high success rate for patients with Hunner lesions in whom more conservative options, including endoscopic treatment, had failed. The success rate was low for patients without Hunner lesions. A 3 to 4-month trial is sufficient time to assess response. Adverse events were common and led to discontinuation of cyclosporine A for some patients. Close monitoring is needed, especially for blood pressure and renal function.

50 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The American Urological Association recently developed guidelines to assist clinicians who evaluate and treat interstitial cystitis/bladder pain syndrome. Knowledge in this area continues to advance, and some of the guideline statements differ from what clinicians may have been previously taught. This review includes the 27 guideline statements, which address both evaluation and treatment. This review lists the guideline statements and, when applicable, comments on their practical implementation and the most recent research. Practical information includes the following: key questions that help in the differential diagnosis, when to perform cystoscopy and urodynamics, how to recognize and treat Hunner lesions, useful practical resources for patients and clinicians, information on elimination diet and stress management, initial selection of oral and intravesical medications, and description of advanced treatment options (limited to dedicated, experienced clinicians).
    Current Urology Reports 07/2012; 13(5):394-401. DOI:10.1007/s11934-012-0263-z · 1.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The efficacy of adalimumab in the treatment of interstitial cystitis/bladder pain syndrome was investigated in a phase III, randomized, double blind, placebo controlled, proof of concept study. Interstitial cystitis/bladder pain syndrome patients were randomized to receive SQ adalimumab 80 mg loading dose followed by 40 mg every 2 weeks or SQ placebo for 12 weeks and outcome measures were assessed. Incidences of adverse events were assessed. Of the 43 patients, 21 received adalimumab and 22 received placebo. Of patients who received adalimumab, there was a statistically significant improvement demonstrated in the O'Leary-Sant Interstitial Cystitis Symptom and Problem Indexes (p = 0.0002), Interstitial Cystitis Symptom Index (p = 0.0011), Interstitial Cystitis Problem Index (p = 0.0002), and Pelvic Pain, Urgency, Frequency scale (p = 0.0017) at 12 weeks compared to baseline. At 12 weeks 11 of 21 (53%) of the adalimumab group had a ≥ 50% improvement in global response assessment (p = ≤0.0001). There was not a statistically significant improvement in any outcome measure in patients receiving adalimumab compared to placebo. There were no significant adverse events. Adalimumab treatment demonstrated a statistically significant improvement in outcome measures compared to baseline in patients with moderate to severe interstitial cystitis/bladder pain syndrome. Adalimumab failed to demonstrate positive proof of concept compared to placebo due to a significant placebo effect.
    The Journal of urology 06/2013; 191(1). DOI:10.1016/j.juro.2013.06.038 · 4.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To describe drugs targeting urinary bladder to treat bladder dysfunctions such as OAB, NDO and bladder pain syndrome. Pubmed search for efficacy, mode of action and side effects for each molecule. Additional data were searched from the French regulatory agencies web sites (HAS and ANSM). Anticholinergics antimuscarinics remain the first-line treatment option for both OAB and NDO. Beta-3 adrenergics emerges as a new therapeutic class for OAB. Post approval safety as well as association with other micturition cycle's drugs need to be evaluated. Phosphodiesterase 5 inhibitors are effective to treat BPH-related LUTS including storage symptoms. Botulinum toxin type A injections within the detrusor are effective and approved to treat NDO in MS and spinal cord injured patients voiding with clean intermittent catheterization. Evaluation of such approach to treat OAB is ongoing. Drug therapy for bladder pain syndrome has limited efficacy including pentosan polyphosfate despite it has a temporary autorisation. There is no drug treatment to restore or improve bladder contraction. Armamenterium to treat bladder dysfunction has recently increased. Three new therapeutic classes emerged. Careful post approval evaluation is mandatory and study of these drugs' combination is expected. Results should drive changes in bladder dysfunction treatment algorithms.
    Progrès en Urologie 11/2013; 23(15):1271-86. DOI:10.1016/j.purol.2013.09.020 · 0.66 Impact Factor
Show more